2018
Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome
Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. Clinical Therapeutics 2018, 40: 952-962.e2. PMID: 29724499, DOI: 10.1016/j.clinthera.2018.04.006.Peer-Reviewed Original ResearchConceptsMetastatic neuroendocrine tumorsTelotristat ethylCarcinoid syndromePlacebo TIDWeek 12Neuroendocrine tumorsMetabolic parametersNutritional statusDouble-blind treatment periodWeight gainWeight lossUncontrolled carcinoid syndromeSomatostatin analogue therapyBowel movement frequencyStatistical analysis planOverall nutritional statusAnalogue therapyDiarrhea severityTreatment periodPatientsSyndromeWeight changeAnalysis planMovement frequencyTumors
2017
Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor
Gerson JN, Witteles RM, Chang DT, Beygui RE, Iagaru AH, Kunz PL. Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor. Pancreas 2017, 46: 1381-1385. PMID: 29040196, DOI: 10.1097/mpa.0000000000000932.Peer-Reviewed Original ResearchConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsCarcinoid syndromeRight upper quadrant abdominal painUpper quadrant abdominal painMetastatic pancreatic neuroendocrine tumorsRight-sided heart diseaseQuadrant abdominal painPulmonic valve replacementAbdominal painSystemic chemotherapyTreatable complicationHormone excessSerum serotoninValve replacementHeart diseaseHeterogeneous groupSyndromeElevated levelsTumorsDiseaseImportant entityDyspneaEmesisPain
2016
Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period
Horsch D, Kulke M, Caplin M, Anthony L, Bergsland E, Oberg K, Welin S, Warner R, Lombard-Bohas C, Kunz P, Valle J, Fleming D, Lapuerta P, Banks P, Pavel M. Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period. Endocrine Abstracts 2016 DOI: 10.1530/endoabs.46.oc3.Peer-Reviewed Original ResearchAssessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviews
Anthony L, Horsch D, Ervin C, Kulke M, Pavel M, Bergsland E, Caplin M, Oberg K, Warner R, Kunz P, Metz D, Pasieka J, Pavlakis N, DiBenedetti D, Haydysch E, Yang Q, Jackson S, Arnold K, Law L, Lapuerta P. Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviews. Endocrine Abstracts 2016 DOI: 10.1530/endoabs.46.p11.Peer-Reviewed Original Research422PD Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome
Kulke M, Hörsch D, Caplin M, Anthony L, Bergsland E, Oberg K, Welin S, Warner R, Bohas C, Kunz P, Grande E, Valle J, Lapuerta P, Banks P, Jackson S, Jiang W, Biran T, Pavel M. 422PD Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome. Annals Of Oncology 2016, 27: vi138. DOI: 10.1093/annonc/mdw369.07.Peer-Reviewed Original Research438P Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT study
Wolin E, Fisher G, Kunz P, Liyanage N, Lowenthal S, Mirakhur B, Pommier R, Shaheen M, Vinik A. 438P Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT study. Annals Of Oncology 2016, 27: vi143. DOI: 10.1093/annonc/mdw369.23.Peer-Reviewed Original Research440P Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study
Fisher G, Wolin E, Kunz P, Liyanage N, Mirakhur B, Lowenthal S, Pommier R, Shaheen M, Vinik A. 440P Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study. Annals Of Oncology 2016, 27: vi144. DOI: 10.1093/annonc/mdw369.25.Peer-Reviewed Original ResearchLonger Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study: 2016 ACG Presidential Poster Award
Fisher G, Wolin E, Kunz P, Liyanage N, Mirakhur B, Lowenthal S, Pommier R, Shaheen M, Vinik A. Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study: 2016 ACG Presidential Poster Award. The American Journal Of Gastroenterology 2016, 111: s457-s458. DOI: 10.14309/00000434-201610001-01052.Peer-Reviewed Original ResearchEfficacy of Lanreotide Autogel/Depot (LAN) vs Placebo (PBO) for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Study
Wolin E, Fisher G, Kunz P, Liyanage N, Lowenthal S, Mirakhur B, Pommier R, Shaheen M, Vinik A. Efficacy of Lanreotide Autogel/Depot (LAN) vs Placebo (PBO) for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Study. The American Journal Of Gastroenterology 2016, 111: s468. DOI: 10.14309/00000434-201610001-01076.Peer-Reviewed Original ResearchEfficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period
Hörsch D, Kulke M, Caplin M, Anthony L, Bergsland E, Öberg K, Welin S, Warner R, Lombard-Bohas C, Kunz P, Grande E, Valle J, Fleming D, Lapuerta P, Jackson S, Zambrowicz B, Sands A, Pavel M. Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period. Zeitschrift Für Gastroenterologie 2016, 54 DOI: 10.1055/s-0036-1587175.Peer-Reviewed Original Research
2015
Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide Therapy
Fisher G, Wolin E, Kunz P, Liyanage N, Gomez-Panzani E, Lowenthal S, Pommier R, Shaheen M, Vinik A. Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide Therapy. The American Journal Of Gastroenterology 2015, 110: s1007. DOI: 10.14309/00000434-201510001-02424.Peer-Reviewed Original Research37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial)
Kulke M, Horsch D, Caplin M, Anthony L, Bergsland E, Oberg K, Welin S, Warner R, Lombard-Bohas C, Kunz P, Grande E, Valle J, Fleming D, Lapuerta P, Banks P, Jackson S, Wheeler D, Zambrowicz B, Sands A, Pavel M. 37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial). European Journal Of Cancer 2015, 51: s728. DOI: 10.1016/s0959-8049(16)31951-7.Peer-Reviewed Original ResearchRole of somatostatin analogues in the treatment of neuroendocrine tumors.
Narayanan S, Kunz PL. Role of somatostatin analogues in the treatment of neuroendocrine tumors. Journal Of The National Comprehensive Cancer Network 2015, 13: 109-17; quiz 117. PMID: 25583773, DOI: 10.6004/jnccn.2015.0012.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsSomatostatin analoguesTumor controlTreatment of NETsSystemic tumor controlHormone-related symptomsManagement of patientsRare epithelial neoplasmAdvanced diseaseHormone excessSymptom managementNeuroendocrine differentiationEpithelial neoplasmsGastrointestinal tractPatientsTumorsTreatmentDiarrheaNeoplasmsLungSerotoninSyndromeSymptomsManagementMainstay